Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer

Chem Biol Interact. 2023 Jan 5:369:110297. doi: 10.1016/j.cbi.2022.110297. Epub 2022 Dec 7.

Abstract

The need for innovative anticancer treatments with high effectiveness and low toxicity is urgent due to the development of malignancies that are resistant to chemotherapeutic agents and the poor specificity of existing anticancer treatments. Chalcones are 1,3-diaryl-2-propen-1-ones, which are the precursors for flavonoids and isoflavonoids. Chalcones are readily available from a wide range of natural resources and consist of very basic chemical scaffolds. Because the ease with which the synthesis it allows for the production of several chalcone derivatives. Various in-vitro and in-vivo studies indicate that naturally occurring and synthetic chalcone derivatives exhibit promising biological activities against cancer hallmarks such as proliferation, angiogenesis, invasion, metastasis, inflammation, stemness, and regulation of cancer epigenetics. According to their structure and functional groups, chalcones derivatives and their hybrid compounds exert a broad range of biological activities through targeting key elements and signaling molecules relevant to cancer progression. This review will provide valuable insights into the latest updates of chalcone groups as anticancer agents and extensively discuss their underlying molecular mechanisms of action.

Keywords: Anticancer; Cancer; Chalcones; Chemotherapy; Pharmacology; Tumor.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Chalcone* / therapeutic use
  • Chalcones* / chemistry
  • Chalcones* / pharmacology
  • Chalcones* / therapeutic use
  • Humans
  • Neoplasms* / drug therapy
  • Signal Transduction

Substances

  • Chalcones
  • Chalcone
  • Antineoplastic Agents